Vetr upgraded shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) from a strong sell rating to a strong-buy rating in a research report sent to investors on Thursday. They currently have $72.50 price objective on the biopharmaceutical company’s stock.
A number of other analysts have also recently commented on the stock. FBR & Co reiterated an outperform rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, March 7th. Needham & Company LLC reissued a buy rating and issued a $68.00 price objective (down from $98.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 9th. JMP Securities set a $69.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a buy rating in a research report on Friday, February 3rd. Ladenburg Thalmann Financial Services began coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 2nd. They issued a buy rating and a $75.00 price objective on the stock. Finally, Chardan Capital increased their price objective on shares of Alnylam Pharmaceuticals from $69.00 to $97.00 and gave the company a buy rating in a research report on Monday, January 9th. Seven analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $64.53.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 59.71 on Thursday. Alnylam Pharmaceuticals has a 12 month low of $31.38 and a 12 month high of $80.11. The firm’s market capitalization is $5.14 billion. The stock’s 50 day moving average is $47.17 and its 200 day moving average is $48.26.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Wednesday, February 8th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.02. The firm earned $17.50 million during the quarter, compared to analysts’ expectations of $10.66 million. Alnylam Pharmaceuticals had a negative net margin of 869.63% and a negative return on equity of 37.25%. The company’s revenue for the quarter was up 130.3% compared to the same quarter last year. During the same quarter last year, the company posted ($1.07) earnings per share. Equities research analysts forecast that Alnylam Pharmaceuticals will post ($5.08) earnings per share for the current fiscal year.
Your IP Address:
In other Alnylam Pharmaceuticals news, Director Philip A. Sharp sold 15,000 shares of the stock in a transaction dated Wednesday, January 25th. The shares were sold at an average price of $37.95, for a total transaction of $569,250.00. Following the sale, the director now directly owns 155,795 shares in the company, valued at $5,912,420.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.00% of the company’s stock.
A number of large investors have recently made changes to their positions in the company. Mn Services Vermogensbeheer B.V. increased its stake in shares of Alnylam Pharmaceuticals by 4.6% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,974 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 87 shares during the last quarter. Neuberger Berman Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $205,000. Notis McConarty Edward purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $229,000. Hall Laurie J Trustee purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $160,000. Finally, Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $266,000. Hedge funds and other institutional investors own 88.70% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.